QNCX vs. ATRA, VSTM, VTGN, SELB, VXRT, CRDF, SGMO, LIFE, VIGL, and DBVT
Should you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Atara Biotherapeutics (ATRA), Verastem (VSTM), Vistagen Therapeutics (VTGN), Selecta Biosciences (SELB), Vaxart (VXRT), Cardiff Oncology (CRDF), Sangamo Therapeutics (SGMO), aTyr Pharma (LIFE), Vigil Neuroscience (VIGL), and DBV Technologies (DBVT). These companies are all part of the "medical" sector.
Atara Biotherapeutics (NASDAQ:ATRA) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk, institutional ownership and community ranking.
Atara Biotherapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
Atara Biotherapeutics received 429 more outperform votes than Quince Therapeutics when rated by MarketBeat users.
Quince Therapeutics has a net margin of 0.00% compared to Quince Therapeutics' net margin of -671.70%. Atara Biotherapeutics' return on equity of -36.72% beat Quince Therapeutics' return on equity.
In the previous week, Atara Biotherapeutics had 3 more articles in the media than Quince Therapeutics. MarketBeat recorded 4 mentions for Atara Biotherapeutics and 1 mentions for Quince Therapeutics. Atara Biotherapeutics' average media sentiment score of 1.87 beat Quince Therapeutics' score of 0.99 indicating that Quince Therapeutics is being referred to more favorably in the news media.
Atara Biotherapeutics presently has a consensus price target of $28.00, indicating a potential upside of 4,891.98%. Given Quince Therapeutics' higher possible upside, analysts clearly believe Atara Biotherapeutics is more favorable than Quince Therapeutics.
Quince Therapeutics has lower revenue, but higher earnings than Atara Biotherapeutics. Quince Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 3.7% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 16.8% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Quince Therapeutics beats Atara Biotherapeutics on 8 of the 14 factors compared between the two stocks.
Get Quince Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quince Therapeutics Competitors List
Related Companies and Tools
